2cureX strengthens the organisation via the recruitment of a CFO

January 16 | 2019
2cureX AB (“2cureX”) hereby announces that the company has appointed Carit J. Andersen as CFO. Carit J. Andersen will initiate his assignment on January 16, 2019. Carit J. Andersen has over 25 years of experience in financial control and has previously been active in both the private and public sector. Previous assignments include the role as CFO at AstraZeneca A/S. Carit J. Andersen will work part-time in 2cureX and will receive market salary for the assignment.

2cureX has developed IndiTreat®, which is a functional test for choosing the right drug for the right patient. IndiTreat® is intended to be pre-launched on the market already in the second half of 2019 and 2cureX is currently preparing the pre-launch. In order to strengthen the organisation ahead of the market launch, 2cureX has now recruited Carit J. Andersen as part-time CFO for the company. Carit J. Andersen holds an M.Sc. in Business Administration and is the owner of Decisionconsult A/S, which provides consulting to companies in questions regarding financial control and business management. Previous experience includes the role as CFO for AstraZeneca A/S. In his role, Carit J. Andersen will strengthen 2cureX's efforts to achieve commercial success with IndiTreat®.

”2cureX is currently preparing the pre-launch of IndiTreat® and through the recruitment of Carit as CFO we further strengthen the organisation for the market launch. Carit contributes with extensive experience and will be an important part of the exciting journey we have in front of us”, says Ole Thastrup, CEO of 2cureX. 

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 22115399

Certified Adviser

Sedermera Fondkommission

E-mail: ca@sedermera.se

Telephone: +46 40 615 14 15

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented and CE-IVD marked test for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® presents the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal, ovarian and pancreatic cancer.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).